Company Overview of ErgoNex Pharma GmbH
ErgoNex Pharma GmbH, a clinical development company, identifies and develops well-tolerated and effective products for novel and typically underserved indications. It engages in the clinical development and commercialization of Terguride for the treatment of distinct orphan diseases. The company was founded in 2004 and is based in Appenzell, Switzerland.
Founded in 2004
41 71 788 40 65
41 71 788 40 69
Key Executives for ErgoNex Pharma GmbH
Similar Private Companies By Industry
|Acino International AG||Europe|
|AL-S Pharma AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ErgoNex Pharma GmbH, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.